A randomized, double-blind, phase III study comparing biosimilar rituximab (RTXM83) plus CHOP chemotherapy versus a reference rituximab plus CHOP (R-CHOP) in patients with Diffuse Large B-Cell Lymphoma (DLBCL) given as first line
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors mAbxience
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.
- 18 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Jan 2018.
- 10 Jun 2017 Biomarkers information updated